Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants.
Flawless balance sheet and overvalued.
Share Price & News
How has Infant Bacterial Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IBT B's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IBT B underperformed the Swedish Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: IBT B underperformed the Swedish Market which returned 9.4% over the past year.
Price Volatility Vs. Market
How volatile is Infant Bacterial Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StDoes Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Pay Compare Well With Peers?
2 months ago | Simply Wall StTrade Alert: The Chief Operating Officer Of Infant Bacterial Therapeutics AB (publ) (STO:IBT B), Anders Kronström, Has Just Spent kr216k Buying Shares
4 months ago | Simply Wall StDo Directors Own Infant Bacterial Therapeutics AB (publ) (STO:IBT B) Shares?
Is Infant Bacterial Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IBT B's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IBT B's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IBT B is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: IBT B is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IBT B's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IBT B is good value based on its PB Ratio (2.3x) compared to the SE Pharmaceuticals industry average (3.9x).
How is Infant Bacterial Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Infant Bacterial Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Infant Bacterial Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Infant Bacterial Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Infant Bacterial Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IBT B is currently unprofitable.
Growing Profit Margin: IBT B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IBT B is unprofitable, and losses have increased over the past 5 years at a rate of -25.8% per year.
Accelerating Growth: Unable to compare IBT B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBT B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).
Return on Equity
High ROE: IBT B has a negative Return on Equity (-8.69%), as it is currently unprofitable.
How is Infant Bacterial Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: IBT B's short term assets (SEK510.4M) exceed its short term liabilities (SEK11.6M).
Long Term Liabilities: IBT B has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IBT B is debt free.
Reducing Debt: IBT B has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IBT B has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IBT B has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.6% each year
What is Infant Bacterial Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IBT B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IBT B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IBT B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IBT B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IBT B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Staffan Strömberg (52yo)
Mr. Staffan Strömberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Strömberg serves as Vice President of Development and Regulatory Affairs at ...
CEO Compensation Analysis
Compensation vs Market: Staffan's total compensation ($USD345.12K) is above average for companies of similar size in the Swedish market ($USD221.38K).
Compensation vs Earnings: Staffan's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||7.42yrs||kr3.22m||0.78% SEK9.2m|
|Chief Operating Officer||2.42yrs||kr500.00k||0.028% SEK332.9k|
|Head of R&D and Chief Scientific Officer||2.83yrs||kr150.00k||0.51% SEK6.0m|
|Chief Financial Officer||3.42yrs||kr1.65m||0.055% SEK642.7k|
|Chief Medical Officer||2.08yrs||no data||no data|
Experienced Management: IBT B's management team is considered experienced (2.8 years average tenure).
|Independent Director||4.75yrs||kr100.00k||0.032% SEK374.8k|
|Independent Director||3.08yrs||kr100.00k||0.00027% SEK3.2k|
|Independent Director||2.08yrs||kr100.00k||no data|
|Independent Director||3.08yrs||kr100.00k||no data|
Experienced Board: IBT B's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Infant Bacterial Therapeutics AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Infant Bacterial Therapeutics AB (publ)
- Ticker: IBT B
- Exchange: OM
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr1.179b
- Shares outstanding: 11.23m
- Website: https://www.ibtherapeutics.com
Number of Employees
- Infant Bacterial Therapeutics AB (publ)
- Bryggargatan 10
- Stockholm County
- 111 21
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IBT B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Mar 2016|
|9IB||BST (Boerse-Stuttgart)||Yes||Class B Shares||DE||EUR||Mar 2016|
|IBTBS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||SEK||Mar 2016|
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 00:20|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.